Seminars in Hematology
Volume 45 , Pages S35-S37 , April 2008

A Prospective, Observational, Post-approval Registry of Inhibitor Patients Treated With Multiple or Single Doses of Recombinant Activated Factor VII

  • Hervé Chambost

      Affiliations

    • Corresponding Author InformationAddress correspondence to Hervé Chambost, MD, Service de Pédiatrie et d'Hématologie Pédiatrique, CHU Timone, 385 Boulevard Jean Moulin, 13385 Marseille, CEDEX 05, France.

References 

  1. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: A single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost. 2003;1:450–455
  2. Kenet G. High-dose recombinant factor VIIa therapy in hemophilia patients with inhibitors. Semin Hematol. 2006;43(suppl 1):S108–S110
  3. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost. 1998;80:912–918
  4. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia. 2005;11:100–106
  5. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost. 2006;4:367–371
  6. Komvilaisak P, Connolly B, Naqvi A, Blanchette V. Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders. Haemophilia. 2006;12(suppl 6):87–93
  7. Carr ME, Martin EJ, Kuhn JG, Seremetis SV. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion. Thromb Haemost. 2003;89:803–811
  8. Proulle V, Hugel B, Guillet B, Trichet C, Rafowicz A, Lambert T, et al. Injection of recombinant activated factor VII can induce transient increase in circulating procoagulant microparticles. Thromb Haemost. 2004;91:873–878
  9. He S, Ekman GJ, Hedner U. The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia. J Thromb Haemost. 2005;3:272–279
  10. Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol. 2005;131:645–655
  11. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G, et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors (A multi-centre, randomised, double-blind, cross-over trial). Thromb Haemost. 2006;95:600–605

 STATEMENT OF CONFLICT OF INTEREST: Hervé Chambost serves on an advisory board in the field of hemophilia care for Novo Nordisk France.

PII: S0037-1963(08)00047-4

doi: 10.1053/j.seminhematol.2008.03.007

Seminars in Hematology
Volume 45 , Pages S35-S37 , April 2008

Article Tools